We conducted a meta‐analysis on the available randomized clinical trials (RCTs) to assess the role of resveratrol in lowering C‐reactive protein (CRP) and high‐sensitivity CRP (hs‐CRP) levels, as markers of inflammation, in various inflammator...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=O108421975
2021년
-
0951-418X
1099-1573
SCI;SCIE;SCOPUS
학술저널
6754-6767 [※수록면이 p5 이하이면, Review, Columns, Editor's Note, Abstract 등일 경우가 있습니다.]
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
We conducted a meta‐analysis on the available randomized clinical trials (RCTs) to assess the role of resveratrol in lowering C‐reactive protein (CRP) and high‐sensitivity CRP (hs‐CRP) levels, as markers of inflammation, in various inflammator...
We conducted a meta‐analysis on the available randomized clinical trials (RCTs) to assess the role of resveratrol in lowering C‐reactive protein (CRP) and high‐sensitivity CRP (hs‐CRP) levels, as markers of inflammation, in various inflammatory disorders. Literature search through Medline/PubMed, Scopus, ISI Web of Science, and Cochrane Library yielded 35 RCTs (24 studies for hs‐CRP and 11 studies for CRP). Pooled results revealed that resveratrol supplementation significantly reduced the hs‐CRP (MWD = −0.40 mg/L; 95% CI: −0.70 to −0.09 mg/L; p = .01) and CRP (MWD = −0.31 mg/L; 95% CI: −0.47 to −0.15 mg/L; p < .001) levels in serum. Subgroup analysis revealed that resveratrol in group with ≥10 weeks significantly reduces hs‐CRP levels (MWD = −0.48 mg/L; 95% CI: −0.92 to −0.04 mg/L; p = .03) and CRP (WMD = −0.47 mg/L, 95% CI = −0.69 to −0.25, p < .001). A dose of ≥500 mg/day supplementation improves the levels of CRP, but not hs‐CRP. This meta‐analysis demonstrates that resveratrol consumption is effective in lowering the levels of CRP and hs‐CRP in inflammatory conditions, especially if supplementation takes place for ≥10 weeks with ≥500 mg/day.